Current stage-Stage III (Advanced) - Page 2 of 2 Posts on Medivizor
Navigation Menu

Current stage-Stage III (Advanced) Posts on Medivizor

Is R-CHOP chemotherapy an effective first-line treatment for patients with grade 3 follicular lymphoma?

Posted by on Jan 7, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the long-term outcomes of patients with grade 3 follicular lymphoma (FLG3) who received first-line R-CHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). The study concluded that this regimen is an effective first-line treatment for patients with FLG3, especially in those with less...

Read More

Is chemotherapy with brentuximab vedotin better than ABVD for treating advanced classical Hodgkin’s lymphoma?

Posted by on Dec 30, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study determined the effectiveness and safety of brentuximab vedotin (Adcetris) administered with AVD (doxorubicin, vinblastine, dacarbazine) chemotherapy for stage 3 or 4 classical HL (Hodgkin’s lymphoma). The study concluded that brentuximab vedotin with AVD was more effective than ABVD (AVD plus bleomycin). Some...

Read More

Does biosimilar filgrastim improve neutropenia in older DLBCL patients receiving chemotherapy?

Posted by on Dec 20, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...

Read More

Is changing treatment intensity after PET scan effective for patients with advanced stage Hodgkin lymphoma?

Posted by on Dec 6, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at changing treatment intensity after a PET scan for patients with advanced stage Hodgkin lymphoma. The authors concluded that reducing treatment intensity for patients with a negative PET scan can reduce negative side effects and improve long-term outcomes. Some background Advanced stage Hodgkin lymphoma (HL) can...

Read More

Brentuximab vedotin as a first-line treatment for advanced Hodgkin’s lymphoma

Posted by on Dec 2, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate if a treatment combination including brentuximab vedotin (Adcetris) would be effective in treating patients with advanced Hodgkin’s lymphoma. This study concluded that treatment combinations with and without brentuximab vedotin were effective but one (BrECADD) was associated with fewer side...

Read More

Comparison between rituximab and CT-P10 biosimilar medication for the treatment of patients with advanced stage follicular lymphoma

Posted by on Oct 7, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab (Rituxan) and CT-P10 treatments for patients with previously untreated advanced stage follicular lymphoma. The study concluded that CT-P10 is just as safe and effective as name-brand rituximab.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly treated...

Read More

Comparison of rituximab and GP2013, a biosimilar medication, in the treatment of patients with follicular lymphoma

Posted by on Oct 2, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared rituximab and GP2013 treatments in patients with previously untreated advanced stage follicular lymphoma. The study concluded that patients treated with GP2013 had similar outcomes to patients treated with rituximab.  Some background Follicular lymphoma (FL) is a type of non-Hodgkin lymphoma. It is commonly...

Read More

Looking for patients with HIV-associated Hodgkin’s lymphoma to test an immunotherapy

Posted by on Aug 23, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 1/2 clinical trial will test the safety and effectiveness of brentuximab vedotin (SGN-35) in treating HIV-associated Hodgkin’s lymphoma. The primary outcome will be measured by the maximum tolerated dose (due to side effects) and the time to disease progression. The details Brentuximab vedotin is a therapy that...

Read More

Combining bendamustine and rituximab improves time to disease progression in follicular and mantle-cell lymphomas

Posted by on Jun 14, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the use of the combination of bendamustine (Treanda) and rituximab (Rituxan) as a firstline treatment in patients with follicular or mantle cell lymphoma. This study concluded that this treatment combination was more effective than the standard treatment of rituximab plus CHOP chemotherapy. Some background The...

Read More

Looking for young Hodgkin lymphoma patients to test the safety and effectiveness of combined treatment with brentuximab vedotin and chemotherapy

Posted by on Apr 10, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 3 trial aims to test the safety and effectiveness of a combined treatment with brentuximab vedotin (BV; Adcetris) and combination chemotherapy in younger patients with recently diagnosed Hodgkin lymphoma. The main outcome to be measured will be the side effects related to treatment and the response of the tumor to the...

Read More

What is the role of combined chemotherapy and radiation in early-stage Hodgkin lymphoma?

Posted by on Mar 11, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study explored whether radiation therapy was necessary in patients with early-stage Hodgkin lymphoma. The study concluded that disease progression occurred more often in patients who did not undergo radiation. Some background The standard treatment option for early stage Hodgkin lymphoma is chemotherapy followed by radiation....

Read More

Nivolumab: a new treatment option for Hodgkin lymphoma that has relapsed or not responded to treatment

Posted by on Dec 20, 2016 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the use of nivolumab (Opdivo) in patients with heavily pretreated Hodgkin lymphoma. The authors concluded that nivolumab was effective and safe in these patients. Some background PD-1 is a protein that slows the immune response. Many cancer cells use the PD-1 pathway to block the immune system from attacking...

Read More